Literature DB >> 8222284

Genetic and molecular heterogeneity of breast cancer cells.

R Callahan1, C Cropp, G R Merlo, F Diella, T Venesio, R Lidereau, A P Cappa, D S Lisicia.   

Abstract

We have undertaken a systematic study of primary human breast tumor DNAs to identify and characterize frequently occurring somatic mutations. Loss of heterozygosity (LOH) was found on chromosomes 1p (37%), 1q (20%), 3p (30%), 7 (41%), 13q (30%), 17p (49%), 17q (29%) and 18q (34%) in our tumor DNA panel. Specific subsets of tumors could be defined based on the particular collection of mutations they contained. One goal of these studies has been to determine whether there is a significant association between specific mutations and clinical parameters of the disease. We have found that LOH on chromosome 17p in tumor DNAs is associated with breast tumors having a high proliferative index and that LOH on chromosome 7 is associated with patients having a poor prognosis. Our analysis of chromosome 17 suggests that there may be as many as four tumor suppressor genes affected in primary human breast tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222284     DOI: 10.1016/0009-8981(93)90238-y

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Decreased expression of the DCC gene in human breast carcinoma.

Authors:  K Wakita; N Kohno; Y Sakoda; Y Ishikawa; M Sakaue
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 2.  The p53-estrogen receptor loop in cancer.

Authors:  C Berger; Y Qian; X Chen
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

Review 3.  MMTV-induced mutations in mouse mammary tumors: their potential relevance to human breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas.

Authors:  Z M Sheng; A Marchetti; F Buttitta; M H Champeme; D Campani; M Bistocchi; R Lidereau; R Callahan
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.